The growth of the EPS is critical in understanding the current valuation of Aerpio Pharmaceuticals. I will do my best to analyze this stock, but there is limited information, therefore please check back later by doing a search here or going to the tag page for the stock symbol ARPO here. The long-term trend in EPS shows how well the management of Aerpio Pharmaceuticals is adding value for shareholders.
Aerpio Pharmaceuticals is in the biotechnology industry and is in the healthcare sector. Aerpio Pharmaceuticals Inc is a biopharmaceutical company. It focuses on advancing first-in-class treatments for ocular diseases.
Previous Intraday Performance:
The ARPO shares had a previous change of -7.01% which opened at 3.64 and closed at 3.45. It moved to an intraday high of 3.65 and a low of 3.34.
Over the last five trading days, ARPO shares returned 2.37% and in the past 30 trading days it returned 115.63%. Over three months, it changed 75.13%. In one year it has changed -26.44% and within that year its 52-week high was 5.20 and its 52-week low was 1.56. ARPO stock is 121.15% above its 52 Week Low.
Our calculations result in a 200 day moving average of 3.19 and a 50 day moving average of 2.58. Right now, ARPO stock is trading 8.26% above its 200 day moving average.
The company has a market cap of $140.0m with 40.6m shares outstanding and a float of 40.3m shares. Trading volume was 201,147 shares and has experienced an average volume of 156,001 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.
The last annual reported EPS for Aerpio Pharmaceuticals was -0.39 which ended on 31st of December 2017. Based on 1 analyst estimate, the estimated EPS for the next quarter is -0.18.
Below was the last reported quarterly earnings per share:
Indicators Also to Watch:
Based on the latest filings, there is 1.10% of insider ownership and 30.20% of institutional ownership.
I calculated the beta to be 3.97
Based on last reported financials, the company’s return on equity is -18.04%, return on assets is -16.87%, profit margin is -9.32%, price-to-sales is 7.47 and price-to-book is 2.11.
Company Score Card:
Results are out of six:
0 : Growth Expectations Result
6 : Financial Safety Result
0 : Past Performance Result
1 : Valuation Result
0 : Dividend Safety Result
1 : Overall Result